An analysis of pooled data from two large finerenone trials identified key risk factors for hyperkalemia in patients with CKD ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Post hoc results support the initiation of SGLT2 inhibitors in patients with diabetic nephropathy regardless of iron deficiency. Canagliflozin treatment may improve iron markers and hemoglobin levels ...

Global type 1 diabetes cases are on the rise, especially in low-income countries, highlighting an urgent need for targeted ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Bayer has launched a digital patient support package in England designed to help people with type 2 diabetes look after the health of their kidneys and avoid progression to chronic kidney disease ...

Diabetes may play a role in your weight, including weight loss, when you have type 1 or type 2 diabetes. This can be a symptom of unmanaged or undiagnosed diabetes, but it can also be due to other ...

Johnson & Johnson's Invokana (canagliflozin) meanwhile also has an indication for diabetic kidney disease, but has been affected by side effect concerns which – while resolved – have sent its ...

architectures learn the representation of homogenous graphs with one type of relationship connecting two nodes. However, multi-view graphs, where each view represents a type of relationship among ...